T2 Biosystems Inc (FRA:3T2)
€ 4.06 -0.15 (-3.56%) Market Cap: 67.24 Mil Enterprise Value: 106.99 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 34/100

T2 Biosystems Inc Analyst and Investor Day Transcript

Apr 12, 2022 / 04:00PM GMT
Release Date Price: €50.24 (+15.23%)
John J. Sperzel
T2 Biosystems, Inc. - President, CEO & Chairman

I'm John Sperzel, Chairman and CEO at T2 Biosystems. Welcome to our 2022 Analyst and Investor Day.

I'll start with our safe harbor statement, which can be found in the Investor Relations section of the company's website. I'll remind you that our presentation may contain forward-looking statements and that actual results may differ from these statements.

Today's agenda includes a company overview, which will be led by me; a panel discussion led by our Chief Medical Officer, Dr. Aparna Ahuja; our commercial strategy, led by our Chief Commercial Officer, Brett Giffin; product pipeline, led by our Senior Vice President of Science Research and Development, Roger Smith; financial summary, led by our Chief Financial Officer, John Sprague; and a Q&A session with the management team.

Let's start with the company overview. Our mission is to fundamentally change the way medicine is practiced through transformative culture-independent diagnostics that improve the lives of patients around the world.

We have

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot